Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-03

Clinical Trial Update: Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm [Phase 2]

View source ↗

Summary

A Phase 2 exploratory study of dipraglurant (ADX48621) for blepharospasm and dystonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dipraglurant (dipraglurant)

Snippet

Sponsor: Addex Pharma S.A. | Conditions: Blepharospasm, Dystonia | Phase 2 | Status: COMPLETED